The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Gastroparesis: Clinical Evaluation of Drugs for Treatment.'' This draft guidance is intended to provide FDA's current thinking regarding clinical trial design and clinical endpoint assessments to support development of drugs for the treatment of diabetic and idiopathic gastroparesis.
Document
Gastroparesis: Clinical Evaluation of Drugs for Treatment; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Gastroparesis: Clinical Evaluation of Drugs for Treat...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
80 FR 43781
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Gastroparesis: Clinical Evaluation of Drugs for Treatment; Draft Guidance for Industry; Availability,” thefederalregister.org (July 23, 2015), https://thefederalregister.org/documents/2015-18023/gastroparesis-clinical-evaluation-of-drugs-for-treatment-draft-guidance-for-industry-availability.